Phase III DREAMM-8 Trial Shows Efficacy of Blenrep Combo Over Standard of Care for Relapsed/Refractory Multiple Myeloma
Blenrep (belantamab mafodotin) combined with pomalidomide plus dexamethasone showed favorable progression-free survival compared with standard of care in the second-line and later treatment of relapsed or refractory multiple myeloma.
Image credit: freshidea | stock.adobe.com
GSK’s Blenrep (belantamab mafodotin) combined with pomalidomide plus dexamethasone (PomDex) achieved the primary endpoint of progression-free survival (PFS) compared with standard of care bortezomib plus PomDex in the second-line and later treatment of relapsed or refractory multiple myeloma (RRMM) in the Phase III DREAMM-8 trial.1 These data follow similar positive findings for Blenrep from the Phase III DREAMM-7 trial, in which the drug combined with bortezomib plus dexamethasone (BorDex) produced a significant improvement in median PFS in the second-line and later treatment of RRMM compared with standard of care combination therapy.2
“The results seen in both DREAMM-7 and DREAMM-8 provide strong clinical evidence of the robust efficacy shown with [Blenrep] in use with standard of care combinations. We now look forward to discussing these data with regulators,” Hesham Abdullah, GSK senior vice president, Global Head Oncology, R&D, said in a press release. “If approved, we believe these combinations have the potential to redefine the treatment of relapsed or refractory multiple myeloma and advance the standard of care. This is exciting news for patients given the high unmet medical need for both efficacious and easily administered therapies with differing mechanisms of action.”1
Blenrep is a first-in-class anti-BCMA therapy that was granted accelerated approval by the FDA in August 2020 for adult patients with RRMM previously administered at least four treatments that included an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. The antibody-drug conjugate has demonstrated antitumor activity in multiple myeloma cells as well as mediated killing of tumor cells via MMAF-induced apoptosis.3
The multicenter, open-label, randomized DREAMM-8 trial compared the efficacy and safety of Blenrep plus PomDex vs. the combination of bortezomib and PomDex in patients with RRMM previously administered at least one prior line of therapy for multiple myeloma, including a lenalidomide-containing regimen, and with documented disease progression during or following administration of their most recent therapy.
Investigators randomly assigned 302 patients at a 1:1 ratio to receive either Blenrep plus PomDex or bortezomib plus PomDex. In addition to the primary endpoint of PFS, secondary endpoints included overall survival (OS), overall response rate, duration of response, minimal residual disease negativity as assessed by next-generation sequencing, safety, and patient-reported and quality of life outcomes.
At a pre-specified interim analysis that was unblinded early based on a recommendation by an Independent Data Monitoring Committee, investigators found the Blenrep combination significantly improved the time to disease progression or death compared with bortezomib plus PomDex. Investigators reported a positive OS trend in favor of the Blenrep combination at the time of this analysis. The trial will continue to follow the trend in OS, according to GSK. In terms of safety, the tolerability of the Blenrep combination was broadly consistent with the known safety profile of the individual agents.
The DREAMM-7 trial evaluated the efficacy and safety of Blenrep with BorDex compared to the combination of daratumumab and BorDex. Patients administered the Blenrep combination showed a statistically significant and clinically meaningful improvement in PFS with a 59% drop in the risk of disease progression or death compared with the daratumumab plus BorDex combination. At a median follow-up of 28.2 months, median PFS was 36.6 months in the Blenrep combination cohort compared with 13.4 months in the daratumumab BorDex combination cohort.2
References
1. GSK announces positive results from DREAMM-8 phase III trial for Blenrep versus standard of care combination in relapsed/refractory multiple myeloma. GSK. News release. March 7, 2024. Accessed March 7, 2024. https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-dreamm-8-phase-iii-trial-for-blenrep-versus-standard-of-care-combination-in-relapsedrefractory-multiple-myeloma/
2. DREAMM-7 phase III trial shows Blenrep combination nearly tripled median progression-free survival versus standard of care combination in patients with relapsed/refractory multiple myeloma. GSK. News release. February 5, 2024. Accessed March 7, 2024. https://www.gsk.com/en-gb/media/press-releases/dreamm-7-phase-iii-trial-shows-pfs-improvement-and-strong-os-trend-for-blenrep-combo-versus-soc-combo-in-multiple-myeloma/
3. Blenrep. Package insert. GlaxoSmithKline; 2020. Accessed March 7, 2024.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
VERITAC-2 Trial Shows Vepdegestrant Significantly Improves Survival in ESR1-Mutant Breast Cancer
March 24th 2025Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant in patients with ESR1-mutant (ESR1m) advanced or metastatic breast cancer, but did not achieve statistical significance in the overall intent-to-treat population.
